

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: 2012-03-12 | Period of Report: 2012-03-09
SEC Accession No. 0001144204-12-014167

(HTML Version on secdatabase.com)

FILER

BioDrain Medical, Inc.

CIK: **1446159** | IRS No.: **331007393** | State of Incorporation: **MN** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-54361** | Film No.: **12683218**
SIC: **3842** Orthopedic, prosthetic & surgical appliances & supplies

Mailing Address
2060 CENTRE POINTE
BOULEVARD
SUITE 7
MENDOTA HEIGHTS MN
55120

Business Address
2060 CENTRE POINTE
BOULEVARD
SUITE 7
MENDOTA HEIGHTS MN
55120
(612) 850-9460

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2012 (March 9, 2012)

BioDrain Medical, Inc.
(Exact name of Registrant as Specified in its Charter)

Minnesota
(State or Other Jurisdiction of Incorporation)

333-155299
(Commission File Number)

33-1007393
(IRS Employer Identification No.)

2060 Centre Pointe Boulevard, Suite 7
Mendota Heights, Minnesota 55120
(Address of Principal Executive Offices and Zip Code)

(651) 389-4800 (651) 389-4800
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a) Appointment of Officer or Director

Effective March 9, 2012, Josh Kornberg, was elected to the Board of Directors of BioDrain Medical, Inc. Mr. Kornberg is President and founding partner of GPF, a private equity fund based in New York. Prior to founding GPF, Mr. Kornberg served as Chief Investment Officer of The Lightstone Group, a national private equity firm and Director of the Lightstone Value Plus REIT, a public company focused on commercial real estate. Mr. Kornberg served as Director of Acquisitions and Development at ARK Realty Investors, a real estate investment and development firm. He worked in the capital markets group at Morgan Stanley, and also served as Vice President at The RREEF Funds, one of the leading global pension fund advisors.

Atlantic Partners Alliance, founded in 2010, is a healthcare and biotechnology fund dedicated to bridge financing of companies in search of short term capital coupled with consulting expertise to help early stage companies develop business (public listings, sales, marketing, strategic development) and technical (regulatory, clinical staging, product evaluation) strategies. The fund was co-founded by Dr. Samuel Herschkowitz and Joshua Kornberg.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 11, 2012

BIODRAIN MEDICAL, INC.

By: /s/ Kevin R. Davidson

Kevin R. Davidson
Chief Executive Officer,
